000 03673nam a22004455i 4500
001 978-1-4939-8818-1
003 DE-He213
005 20260610083626.0
007 cr nn 008mamaa
008 181025s2018 xxu| s |||| 0|eng d
020 _a9781493988181
_9978-1-4939-8818-1
024 7 _a10.1007/978-1-4939-8818-1
_2doi
050 4 _aRM300-666
072 7 _aMMG
_2bicssc
072 7 _aMED071000
_2bisacsh
072 7 _aMKG
_2thema
082 0 4 _a615
_223
245 1 0 _aEvidence-Based Pharmacovigilance
_h[electronic resource] :
_bClinical and Quantitative Aspects /
_cedited by Andrew Bate.
250 _a1st ed. 2018.
264 1 _aNew York, NY :
_bSpringer New York :
_bImprint: Humana,
_c2018.
300 _aXV, 275 p. 36 illus., 27 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aMethods in Pharmacology and Toxicology,
_x1940-6053
505 0 _aCongenital Malformations -- Pharmacovigilance and the Eye -- Pharmacovigilance of Herbal and Traditional Medicines -- Pediatric Pharmacovigilance: Current Practice and Future Perspectives -- Detecting Safety Issues in Clinical Trials -- Developments and Future Directions of Prescription-Based Observational Cohort Pharmacovigilance -- Electronic Health Record, Transactional Insurance Claims, and Distributed Databases in Pharmacovigilance -- Patient Registries for Safetyness -- Patient-Reported Outcomes in Pharmacovigilance -- Evidence-Based Pharmacovigilance for Medicines Used in Public Health Programs in Africa -- Pharmacoepidemiological Approaches for Population-Based Hypothesis Testing -- Risk Management and Minimization -- Benefit-Risk Assessment in Pharmacovigilance -- Concluding Thoughts.
520 _aThis book examines insights into the latest thinking and core concepts in areas of key methodological endeavor in Pharmacovigilance (PV), which strives to ever more effectively protect patients from harm caused by the medicines they need. Each book chapter tends to have a clear quantitative or clinical slant and an aim to provide an overview of methodological insights within a specific topic, while also providing a perspective on how the area is anticipated to develop in the future. Quantitative chapters focus more on statistical and epidemiological strategies and the thinking that underpins core developments in Pharmacovigilance, whereas clinical chapters focus on clinical methods for detecting hypotheses for and determining side effects of medicinal products as well as misdiagnosis pitfalls. Examples of areas of importance include signal detection, risk management, and risk benefit assessment. Vital and authoritative, Evidence-Based Pharmacovigilance: Clinical and Quantitative Aspects aims to provide readers with a sense of the advances that have occurred in pharmacovigilance methods and approaches, as well as inspiration and motivation to advance the field of pharmacovigilance with a strong sense that there is much more work to be done in ensuring the safe use of medications by patients.
650 0 _aPharmacology.
650 1 4 _aPharmacology.
700 1 _aBate, Andrew.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9781493988167
776 0 8 _iPrinted edition:
_z9781493988174
830 0 _aMethods in Pharmacology and Toxicology,
_x1940-6053
856 4 0 _uhttps://doi.org/10.1007/978-1-4939-8818-1
912 _aZDB-2-PRO
999 _c5298
_d5298